Preclinical model of obesity and ER-positive breast cancer. Preclinical model of obesity and ER-positive breast cancer

Here, we developed a mouse model of diet induced obesity that is graft competent. In this model, we grew an ER-positive breast cancer patient derived tumor. Following ovariectomy and estrogen deprivation therapy, tumors continued to grow in obese but not lean mice. RNAsequencing analysis was performed on tumors from estrogen-supplemented lean mice, and from lean and obese mice after estrogen deprivation. This analysis identified fibroblast growth factor receptor signaling as a potential driver of tumor progression in the context of obesity. Overall design: LFLS E2 N=4; LFLS EWD N=4; HFHS EWD N=4, HFHS E2 N=3